Immune Checkpoint Inhibitors Across Tumor Types: Present and Future

Immune checkpoint inhibitors have transformed cancer treatment across melanoma and many other tumor types, creating new opportunities and new toxicities for dermatologists to understand. This session reviews current and emerging uses of checkpoint blockade, mechanisms of response and resistance, combination strategies, and future directions in immuno-oncology. Dermatology-relevant considerations include cutaneous immune-related adverse events, coordination with oncology, and the expanding role of dermatologists in supportive cancer care.